IMV Inc.
OTCPK:IMVI.F Rapporto sulle azioni
IMV Dividendi e riacquisti
Dividendo criteri di controllo 0/6 IMV non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
n/a
Rendimento del riacquisto
Rendimento totale per gli azionisti n/a Rendimento futuro dei dividendi n/a Crescita dei dividendi n/a Prossima data di pagamento dei dividendi n/a Data di stacco del dividendo n/a Dividendo per azione n/a Rapporto di remunerazione n/a
Aggiornamenti recenti su dividendi e riacquisti
Mostra tutti gli aggiornamenti
IMV Inc. Files Form 15 Sep 23 Nasdaq to Delist the Common Shares of IMV Jul 08
IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index May 12
IMV Receives Nasdaq Delisting Notice May 09
IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial Feb 14
High number of new directors Jan 13
IMV Inc. Announces Board Changes Jan 09 IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million. Dec 22
IMV Inc. has completed a Follow-on Equity Offering in the amount of $9 million. Dec 21
Imv Inc. Announces Initial Data from the Ongoing Phase 2B Vitalize Trial in Patients with R/R Dlbcl Dec 16
IMV Inc. to Report Q3, 2022 Results on Nov 11, 2022 Nov 09 IMV Inc. Announces Board Changes
IMV to cut ~33% workforce amid reorganization Sep 15
High number of new directors Aug 01
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Jul 09
IMV receives Nasdaq non-compliance letter Jul 08
High number of new directors Jul 05
IMV Inc. Announces Andrew Sheldon Not Stand for Re-Election to the Board Jul 01 IMV Inc. announced that it has received $25 million in funding from Horizon Technology Finance Management, LLC Jun 24
IMV Inc. Appoints Michael P. Bailey as Chairman of the Board Apr 23 IMV Inc., Annual General Meeting, Jun 14, 2022 Apr 15
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 18
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL Jan 13
IMV Inc Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts Dec 22
IMV Inc. announces new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients Dec 03
IMV Inc. Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer Dec 01
IMV Inc. Announces Final Topline Results of the Decide1 Clinical Trial Aug 11
CEO & Director Frederic Ors has left the company Aug 05
High number of new directors Jul 31
CEO & Director recently bought US$147k worth of stock Jul 25
Chief Medical Officer Joanne Schindler has left the company Jun 15
IMV names Jeremy Graff as chief scientific officer Jun 09
Imv Inc. Leads Immunotherapy to Be Investigated in Breast Cancer May 11
Independent Director has left the company Apr 07
Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019) Mar 19
IMV Inc. to Report Q4, 2020 Results on Mar 17, 2021 Mar 09
New 90-day high: US$4.36 Feb 05
IMV Reports Update on COVID-19 Vaccine Program Dec 29
IMV's vaccine candidate potentially effective against COVID-19, shares up 16% Dec 28
New 90-day low: US$3.13 Dec 19
Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting Dec 07
IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer Dec 04
IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5% Dec 03
Revenue and earnings beat expectations Nov 13
IMV reports Q3 results Nov 12
IMV Inc. Appoints Andrew Hall as Chief Business Officer Nov 11
IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda® in PD-L1 Positive Patients with r/r DLBCL Nov 10
IMV Inc. Provides Updated Clinical Data from Phase 2 SPiReL Study Evaluating its T Cell Therapy in Combination with Merck’s Keytruda in Patients with R/R DLBCL Nov 06
New 90-day low: US$3.15 Oct 27
IMV Inc Announces That Biomarkers Associated with Clinical Response in Patients with R/R DLBCL Treated with DPX-Survivac Oct 16
New 90-day low: US$3.85 Oct 12
IMV Inc. Provides Updates on Its Vaccine Candidate, DPX-COVID-19, for the Prevention of Infection Caused by the Novel Coronavirus SARS-COV-2 Oct 10
Earnings released Aug 12
IMV Inc. to Report Q2, 2020 Results on Aug 12, 2020 Aug 08
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di IMVI.F siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di IMVI.F siano aumentati.
Rendimento dei dividendi rispetto al mercato IMV Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di IMVI.F rispetto al mercato? Segmento Rendimento dei dividendi Azienda (IMVI.F) n/a Fondo del 25% del mercato (US) 1.3% Top 25% del mercato (US) 4.3% Media del settore (Biotechs) 2.1% Analista previsionale (IMVI.F) (fino a 3 anni) n/a
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di IMVI.F rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di IMVI.F rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di IMVI.F per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché IMVI.F non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}